Asthma and hypertension are complex diseases coinciding more frequently than expected by chance. Unraveling the mechanisms of comorbidity of asthma and hypertension is necessary for choosing the most appropriate treatment plan for patients with this comorbidity. Since both diseases have a strong genetic component in this article we aimed to find and study genes simultaneously associated with asthma and hypertension. We identified 330 shared genes and found that they form six modules on the interaction network. A strong overlap between genes associated with asthma and hypertension was found on the level of eQtL regulated genes and between targets of drugs relevant for asthma and hypertension. this suggests that the phenomenon of comorbidity of asthma and hypertension may be explained by altered genetic regulation or result from drug side effects. In this work we also demonstrate that not only drug indications but also contraindications provide an important source of molecular evidence helpful to uncover disease mechanisms. These findings give a clue to the possible mechanisms of comorbidity and highlight the direction for future research.
Asthma and hypertension affect hundreds of millions of people worldwide 1, 2 and coincide in adults more frequently than expected by chance. Patients with asthma are more likely to have high blood pressure 3 and, in turn, the presence of hypertension is associated with the increased severity of asthma 4 . This association between asthma and hypertension was confirmed in multiple studies of different patient cohorts [3] [4] [5] [6] [7] but its underlying causes remain unknown. The coexistence of two or more diseases, called comorbidity, was shown for many human disorders [8] [9] [10] . Moreover, not only complex disorders demonstrate comorbidity but also several Mendelian diseases coincide with complex disorders 10, 11 . Comorbidity can be direct or inverse 8, 12 , when the presence of one disease protects from the development of another one. For example, the coincidence of neoplasms with several nervous system disorders is lower than expected 13, 14 .
Comorbidity may point to causal relationships between two diseases. For instance, hypertension may cause cardiovascular damage, leading to consequences such as heart failure, stroke, and kidney problems 2 . Alternatively, comorbidity may result from confounder effects, e.g. lifestyle or environmental factors, predisposing to multiple health problems. For instance, smoking is a risk factor for multiple diseases 15 , including hypertension 2 and asthma 1 . Also, stress may trigger asthma attack 1 , and long-term stress exposure is associated with the risk of hypertension 2 . Finally, comorbidity of two diseases may be an effect of a third disease. For instance, obesity is another common risk factor for asthma and hypertension and decreasing of the body-mass index is helpful for management of both diseases 16, 17 .
In addition to these risk factors, some anti-asthmatic drugs may worsen hypertension and vice versa, and several anti-hypertensive drugs are contraindicated in asthma. For example, beta-blockers used to control blood
Results
Genes previously associated with asthma and hypertension. Although the phenomenon of comorbidity of asthma and hypertension has long been known, only a few works discussing genes potentially involved in both diseases or related pathophysiological processes have been published before 2018. We have found six publications which discussed ten genes in total potentially relevant to both asthma and hypertension and summarized the results of our literature search in Table 1 . These studies were mostly focused on genes and their functions and did not aim to discover the mechanisms of comorbidity between the two diseases.
In our recent work 33 , we applied ANDSystem 34, 35 to perform the automatic reconstruction of the associative gene network for asthma and hypertension from scientific literature. The resultant associative network included 205 genes potentially responsible for comorbid asthma and hypertension. We proposed gene prioritization methodology based on ten criteria including relevance scores calculated by state-of-the-art gene prioritization tools 36, 37 , association with biological processes, position in the associative network and evidence of genetic associations and regulations. The IL10, TLR4, and CAT genes had the highest ranks among all candidate genes, and ADRB2 was ranked sixth. Our later works demonstrated experimental evidence supporting possible roles of IL10 and TLR4 in comorbid asthma and hypertension. Drevytska et al. created an animal model of comorbid asthma and hypertension -SHR with OVA-induced asthma -and demonstrated that IL10 knock-down in this model improves cardiac and lung function parameters 38 . Bragina et al. identified expression quantitative trait loci (eQTL) associated with asthma and hypertension comorbidity for CAT, TLR4, ANG and RNASE4 genes on the cohort of 587 individuals from West Siberia 39 . More recently, Saik et al. reanalyzed associative asthma/hypertension network and, based on the cross-talk centrality, proposed ten more immune-related genes for further experimental validation 40 .
All the previous works investigated the genetic basis of asthma/hypertension comorbidity evaluated the relevance of single genes. In contrast with previous studies, in this work, among all the associations extracted from a variety of data sources, we identified and characterized groups of functionally related genes. Our approach aligns with current understanding of asthma and hypertension as complex disorders, which thought to be polygenic and heterogeneous 41, 42 . Yet another advantage of this work is that we incorporated types of associations not considered in previous studies nor provided by large gene-disease association portals, such as Open Targets 43 or DisGeNET 44 . In particular, we included into the analysis genes controlled by eQTLs associated with asthma and hypertension and target genes of drugs contraindicated in these diseases.
the overlap between genes associated with asthma and hypertension independently. Aiming to compose comprehensive lists of genes associated with asthma and hypertension and investigate their overlap, we collected gene-disease associations supported by a variety of evidence types: genetic associations, differential expression, co-occurrence in texts, and targeting by drugs used against asthma and hypertension. Also, to expand these gene lists, we used GWAS hits mapped to known eQTLs and selected genes regulated by these eQTLs. Finally, we hypothesized, that genes targeted by drugs causing adverse effects similar to asthma and hypertension may also be involved in their pathogenesis. Therefore, in addition to drugs that can treat asthma and hypertension, we took into account drugs that exaggerate these diseases and added their targets in the lists of genes for asthma or hypertension.
After combination of gene-disease associations from various evidence sources (see Methods and Fig. 1 ), the lists of 980 genes associated with asthma and 1204 genes associated with hypertension were compiled. Out of them, 330 genes were associated with both diseases according to at least one data source ( Supplementary  Table S1 ). To facilitate further use of associations relevant for asthma and hypertension comorbidity, we added them to GenCoNet database 45 . related genes, we built a functional network of shared asthma/hypertension genes using Cytoscape 46 v3.6.1 strin-gApp 47 v1.3.0 and performed module detection. In this network, two nodes were connected, if corresponding genes are co-expressed or if proteins physically interact or share biological pathways. Only edges representing gene co-expression, physical interactions of encoded proteins and biological pathway sharing, were included in the network. Overall, 257 out of 330 genes (78%) were connected with at least one of other genes. Six tightly interconnected modules were detected using ClusterViz App 48 v1.0.3 EAGLE algorithm 49 (with minimal Clique Size and Complex Size thresholds set to 10) and annotated with overrepresented pathways, GO terms, and tissue-specific gene sets (Supplementary Tables S2A-C provide all significant gene set overlap analysis results).
Module 1 comprised 77 genes was enriched with genes participating in cytokine signaling, in particular, in IL-4, IL-13, and IL-23, and Th17 differentiation pathways. IL-4 and IL-13 regulate inflammatory response to allergen exposure in asthma 50 . IL-23 and Th17 cells are elevated in hypertension 51 and promote neutrophilic inflammation in asthma 52 . A very recent review on the treatment of comorbid asthma and hypertension summarizes implications of cytokine signaling and Th17 cells for both diseases 53 . Module 2 comprised 43 genes participating in the metabolism of xenobiotics and defending the cell from oxidative stress. Reactive oxygen species are generated by airway epithelium cells exposed to irritants, activate immune cells and thought to be implicated in asthma 54 . Hypertension is characterized by elevated oxidative stress biomarkers in blood and increased oxidative damage of vasculature 55, 56 . A large body of evidence confirms roles of antioxidant defence enzymes in asthma [57] [58] [59] and hypertension 60, 61 . Interestingly, a key antioxidant enzyme, catalase (CAT), was also previously associated with comorbid asthma and hypertension 33, 39 . Module 3 enriched with genes involved in extracellular matrix organization and platelet degranulation. Platelets are altered in hypertension 62 and their release products participate in airway inflammation and remodeling in asthma 63 . Module 4 was enriched by genes encoding G protein-coupled receptors and responsible for regulation of blood vessel diameter. This module included adrenoreceptor genes, many of which are targeted by drugs against asthma and hypertension. Module 5 was enriched with genes participating
Gene Functions Evidence
TLR4 pathogen recognition and activation of innate immunity Up-regulated in lungs of spontaneously hypertensive rats (SHR) compared to normotensive ancestor strain (WKY rats) in response to combustion source particulate matter treatment which irritates lungs 96
CXCL2 (MIP-2) suppress hematopoietic progenitor cell proliferation CD14 mediates the innate immune response to bacterial lipopolysaccharides RHOA reorganization of the actin cytoskeleton and regulation of cell shape, attachment, and motility Up-regulated in rodent models of asthma and hypertension; inhibition leads to improvement of both conditions 97 . ROCK inhibitors suppress smooth muscle contraction and may treat arterial hypertension and asthma 98 ROCK1
regulates formation of focal adhesions GNA12, GNA13 signal transduction
These genes encode G-protein subunits transducing the signal from activated GPCR to RhoGEFs activating RHOA. Abnormal G12/13 signaling is involved in the pathogenesis of arterial hypertension and bronchial asthma, among other pathophysiological conditions 99
SLC26A4
encodes transmembrane anion exchanger Madeo et al. 100 reported a variant of SLC26A4 with potentially protective effect for both asthma and hypertension ADRB1, ADRB2 mediate the physiological effects of the epinephrine and norepinephrine
These genes encode proteins targeted by drugs used against asthma and hypertension; some variants are associated with response to anti-hypertensive 101 anti-asthmatic therapy 102 Table 1 . Genes potentially involved in the pathophysiology of asthma and hypertension, according to literature published before 2018. in cytokine signaling. In contrast to module 1, genes from module 5 were associated with interferon gamma response and more specific for CD16-monocytes and sputum, than for neutrophils. Interferon-gamma inhibits Th2-induced inflammation but promotes cytotoxic response 64 . Interferon gamma signaling is implicated in asthma 64 and angiotensin-II-induced hypertension 65 . Module 6 was composed of genes encoding histones, whose modifications define chromatin state and regulate gene expression. Changes of histone modifications are shown in many diseases including asthma 66 and hypertension 67 . Inhibition of histone deacetylases decreases inflammations 68 and demonstrate anti-hypertensive effects 67, 69 . Some modules overlapped in a few genes: MAPK1 and EDN1 belonged to modules 1 and 4, C3 and C5 to modules 2 and 4, STAT1 to modules 1 and 5, and SERPINA1 to modules 2 and 3. Such genes may be responsible for a cross-talk between biological processes represented by modules these genes connect. However, of these six genes, only MAPK1 and STAT1 were associated with asthma or hypertension through evidence other than co-occurrence in texts.
Analysis of evidence types supporting gene-disease associations.
To investigate the contribution of various evidence types to the detection of shared genes, we labeled every gene with the kind of relationship, linking it with asthma or hypertension, and analyzed the distribution of labels among six modules. Figure 2 shows that the distribution of labels over the network does not seem to be random, and the representations of different evidence type labels among modules are not equal. The majority of shared genes (231 of 330) had an association established via text mining by HuGE Phenopedia 70 v2.1 and were supported by at least two independent studies. Moreover, associations of 125 of them were established via text mining only and constituted essential parts of modules 1-4. Although frequent co-occurrence in texts does not seem to be the most confident evidence of association, we could not exclude it from consideration without losing 206 (62%) of shared genes.
We also found that all members of module 6 and almost all of module 5 included genes that are controlled by GWAS-identified eQTLs associated with asthma or hypertension. In total, 107 out of 330 shared genes were regulated by such eQTLs. Since this number significantly exceeded the expected by chance (Fisher's exact test p-value < 6.94e-145; permutation p-value < 10e-4; 10 expected on average), we can hypothesize that these shared genes may have an impact on the development of comorbidity between asthma and hypertension. Importantly, this observation cannot be explained simply by shared GWAS hits. Only one missense variant, rs3184504 in SH2B3 gene, was in the intersection of asthma and hypertension GWAS associations. It was independently associated with hypertension, blood eosinophil count and many other traits and controlled only 39 of 107 genes associated with asthma and hypertension through eQTL regulation. Interestingly, among these 39 genes 5 were up-regulated in blood of patients with hypertension and included in the "blood pressure signature" proposed by Huan et al. 71 : FOS, MYADM, PPP1R15A, S100A10, and TAGAP.
To illustrate the novelty of our findings, we compared our set of shared genes with gene sets obtained from Open Targets v18.02 and DisGeNET v5.0 using trivial disease names. In our list of 330 shared genes, 82 were novel (nodes shown in bold frames in Fig. 2) , i.e. not associated with asthma and hypertension in OpenTargets and DisGeNET. These two large gene-disease association databases use distinct sets of evidence sources and interpret some associations differently. For example, they do not consider gene regulation data for establishing gene-disease associations, although it is implicated in asthma 72 and hypertension 71 . Open Targets and DisGeNET include gene-disease associations obtained directly from GWAS Catalog, where disease-associated variants are mapped to neighboring genes and do not differentiate synonymous and non-synonymous variants. As a result, most of the newly identified shared genes were associated via eQTLs and composed modules 5 and 6.
Adverse drug reactions may mediate comorbidity of asthma and hypertension. We observed more common drugs (and therefore drug targets) relevant to asthma and hypertension than expected by chance. We composed four lists of drugs that influence asthma or hypertension ( Supplementary Table S3 ): drugs with positive effects on asthma or hypertension (i.e. used to treat or relieve their symptoms) and drugs with negative effects on these diseases (i.e. contraindicated or worsening disease symptoms). Eight drugs used to treat hypertension were harmful for asthma patients: timolol, nadolol, sotalol, pindolol, carvedilol, labetalol, propranolol. All these drugs belong to the class of non-selective beta-blockers and may exacerbate asthma 19 . At the same time, seven anti-asthmatic drugs occurred in the list of drugs that may increase the risk of hypertension or elevate blood pressure: triamcinolone, prednisolone, methylprednisolone, dexamethasone, hydrocortisone (corticosteroids) and epinephrine, ephedra, ephedrine (beta-agonists). Both overlaps were statistically significant with p-value < 2.64e-06 and p-value < 4.50e-06, respectively in Fisher's exact test.
To find target genes whose activation or inhibition exhibit positive or negative influence on asthma and hypertension, we performed target overrepresentation analysis in four drug groups. 96 genes were significantly overrepresented among targets of at least one of four drug groups ( Table 2 and Supplementary Table S4 ), only 16 of which were in asthma-hypertension network. Interestingly, 8 of these 16 genes associated with asthma or hypertension through drug evidence appeared in module 4, enriched with genes involved in smooth muscle contraction. Figure 3 summarizes all significant drug targets, their relationships with drugs, and drug effects on asthma and hypertension. Supplementary Table S5 provides this network in tabular format. ADRB1 and ADRB2 were targeted by drugs from all the four groups, and activation and inhibition of beta-adrenoreceptors caused opposite effects on asthma and hypertension. Similarly, NR3C1, a glucocorticoid receptor, was activated by drugs indicated in asthma but potentially harmful for hypertension. ANXA1 is another target of corticosteroid drugs, such as dexamethasone and hydrocortisone, its activation mediates the anti-inflammatory effect via inhibition of phospholipase A2 73 . ANXA1 is up-regulated in blood of hypertensive patients 71 . PTGS2 inhibition seemed to have a negative effect on both diseases, while PTGS1 was overrepresented only among targets of drugs contraindicated in asthma.
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(2019) 9:16302 | https://doi.org/10.1038/s41598-019-52762-w www.nature.com/scientificreports www.nature.com/scientificreports/ Our results agree with prior knowledge about asthma and hypertension medications. It is well known that β -blockers and agonists have opposite effects on asthma and hypertension. Although medications for treating hypertension and asthma target different receptors (ADRB1 blockers have anti-hypertensive effect 2 and ADRB2 agonists have anti-asthmatic effect 1 ), there are many components non-specifically targeting multiple types of adrenoreceptors 19 . Blockers of α 1 and agonists of α 2 -adrenergic receptors cure hypertension 2 , and opposite actions on these receptors may provoke blood pressure elevation. Alternative treatment options for asthma patients who poorly respond to beta-agonists are inhaled or systemic glucocorticoids 74 . Overdosage of glucocorticoids induces elevation of blood pressure, although inhaled glucocorticoids are relatively safe compared to systemic steroids because of their local action 21 . Patients with an elevated level of glucocorticoids due to their overproduction or abnormal metabolism develop Cushing syndrome 75 , characterized by high blood pressure among other symptoms. Other classes of anti-inflammatory drugs, such as non-steroid anti-inflammatory drugs (NSAID) may also influence asthma and hypertension. NSAID-Exacerbated Respiratory Disease (NERD), is a classic example of adverse drug reaction in response to aspirin and some other NSAIDs. NERD is also called aspirin-induced asthma because it resembles main asthma symptoms, such as bronchial obstruction and dyspnea, and is prevalent among asthma patients 76 . NERD is thought to result from PTGS1 inhibition, therefore the usage of PTGS2 selective inhibitors is considered to be relatively safe for asthmatics 77 , but it is associated with a risk of hypertension 78, 79 . Also, NSAIDs may decrease the effect of anti-hypertensive medications 80 .
Discussion
In this study, we investigated the genetic overlap between a pair of comorbid disorders, asthma and hypertension. A correlation of gene perturbation with disease status points to the possible involvement of this gene in the disease mechanism. At the same time, different molecular lesions may have similar effects on the phenotype. These considerations motivated us to construct two sets of genes independently associated with each disease through various perturbation types and investigate their overlap. We found 330 genes simultaneously associated with both diseases and potentially responsible for their comorbidity. Projecting these shared genes to an interaction network revealed six functional modules comprising tightly interconnected genes. We tested these modules for the overrepresentation of GO terms and pathways, tissue-specificity and evidence types supporting gene associations.
We observed an excess of genes jointly controlled by asthma-and hypertension-associated eQTLs in modules enriched with genes involved in interferon-gamma signaling and chromatin assembly. This observation suggests that the coincidence of asthma and hypertension may be at least partially explained by concordantly altered genetic regulation of certain biological processes of functions. Our finding agrees with very recent results Here, nodes represent genes associated with both asthma and hypertension, edges correspond gene interactions (only 257 nodes connected with at least one other node are shown). Genes are colored according to evidence sources (see figure legend) from which associations came from. The size of each node is proportional to the number of evidence sources supporting its association with asthma and hypertension. All 330 genes associated with asthma and hypertension annotated with evidence types supporting associations are listed in Supplementary Table S1. www.nature.com/scientificreports www.nature.com/scientificreports/ published by Li et al. 81 , who analyzed multiple disease pairs and demonstrated that comorbid diseases share significantly more eQTL-regulated transcripts than expected by chance.
We also found more drugs with opposite effects on asthma and hypertension than expected by chance. Based on this observation, we hypothesized that comorbidity might be the result of drug side effects, when drugs against one disease may predispose the patient to the development of another. This particular case of asthma and hypertension demonstrates that genes targeted by contraindicated drugs may also participate in pathophysiologic mechanisms of comorbidity.
An important limitation of this study is the absence of direct validation of the resulting associated gene set. Since the genetic basis of asthma and hypertension comorbidity is poorly understood, we have no gold standard to compare with. Another way of result evaluation would be an experimental validation of gene roles in the comorbidity, which was not in the scope of this work.
The validity of our results is partially confirmed by the presence of some known shared genes in our set. Four genes (ADRB1, ADRB2, TLR4, and CD14) listed in Table 1 appear among 330 genes associated with asthma and hypertension. This limited overlap may be explained by the fact that most of the papers included in Table 1 do not focus on asthma or hypertension and only list them among multiple phenotypes associated with certain genes. Therefore, if associations of these genes with asthma and hypertension do not appear in abstracts, they remain invisible for text mining tools.
Another indirect confirmation of the result validity is our observation that comorbid diseases share many genes controlled by eQTLs. This agrees with the results of Li et al. 81 , obtained independently on different datasets.
Methods
Monogenic associations via hereditary asthma and hypertension. From MalaCards 82 v4.5, and literature 2, 83 we extracted genes that carry mutations causing monogenic syndromes with asthma or hypertension among other symptoms. In total, we found 37 genes associated with familial forms of hypertension or with Mendelian disorders characterized by hypertension. No monogenic forms of asthma were found, although several Mendelian syndromes characterized by frequent asthma attacks considered in the literature 83 . From human phenotype ontology 84 (HPO) we selected phenotype terms related to asthma (HP:0002099 -Asthma, HP:0012042 -Aspirin-induced asthma, HP:0025428 -Bronchospasm) and hypertension (HP:0000822 -Hypertension, HP:0000875 -Episodic hypertension, HP:0004421 -Elevated systolic blood pressure, HP:0004972 -Elevated mean arterial pressure, HP:0005117 -Elevated diastolic blood pressure). We excluded genes associated with specific kinds of hypertension (e.g. ocular hypertension) that are not related to essential hypertension (HP:0007906, HP:0001409, HP:0002092, HP:0002640, HP:0008071, HP:0100817, HP:0005168). Mapping of genes to HPO terms was downloaded from http://compbio.charite.de/jenkins/job/hpo.annotations.monthly/lastStableBuild/, table ALL_SOURCES_FREQUENT_diseases_to_genes_to_phenotypes.txt" available on 26.01.2018. We used gene-phenotype pairs marked as "frequent", which means that this phenotype was manifested in at least 50% patients with a disease. coding GWAS variants. GWAS Catalog 85 v1.0.1 (downloaded on 22.08.2017) includes 29 studies related to asthma which report 407 associations in total (395 unique). In addition, we included 17 associations from 4 studies of asthma-related traits such as NERD, eosinophil count or Immunoglobulin E (IgE) levels. Similarly, 120 associations with hypertension and blood pressure traits were obtained from 16 studies listed in GWAS Catalog. All associations have p-value < 10e-5 (default in GWAS Catalog). Only 29 and 9 single-nucleotide polymorphisms (SNPs) associated with asthma and asthma-related traits and with hypertension and blood pressure respectively were annotated as splice_region_variant, missense_variant, synonymous_variant or non_coding_ transcript_exon_variant and therefore affected transcript sequences.
Regulation. Although only a small fraction of variants discovered in GWAS affects transcripts, about a half of them overlap with eQTLs 86 . From three recent blood eQTL studies [86] [87] [88] comprising thousands of individuals, we obtained lists of eQTL SNPs and overlapped them with variants associated with asthma and hypertension ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRB1, ADRB2 , AGTR1, AGTR2, BDKRB1, CA1, CA4, CACNA1B, CACNA1C, CACNA1D,  CACNA1F, CACNA1H, CACNA1S, CACNA2D1, CACNA2D2, CACNA2D3,  CACNB1, CACNB2, CACNB3, CACNB4, CACNG1, KCNH2, KCNH6, KCNH7,  NR3C2, SCNN1A, SCNN1B, SCNN1D, SCNN1G, SLC12A1, SLC12A3   hypertension  contraindications 94 188 ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1,  ADRB2, ADRB3, ANXA1, FGA, FLT1, FLT4, HTR1A, HTR1B, HTR1D,  HTR1E, HTR1F, HTR2B, HTR2C, HTR7, ITGA2B, ITGB3, MAOA, MAOB,  NR3C1, PAH, PDGFRB, PGR, PLAUR, PLG, PTGS2, SERPINB2, SERPINE1 , SLC18A1, SLC18A2, SLC6A2, SLC6A3, SLC6A4, TAAR1, VKORC1 Table 2 . Genes overrepresented among targets of drugs influencing asthma and hypertension. Target genes significantly enriched in more than one group are shown in bold. Genes ADRB1 and ADRB2 whose potential role in asthma and hypertension was previously discussed are underlined.
in GWAS. Furthermore, we included variants associated with tissue-specific expression from GTEx v6 89 . This dataset contained eQTLs in 44 tissues including whole blood. The details of eQTL data sources used in this study are presented in Table 3 . From each study, we retained only SNP-gene pairs which passed the false discovery rate (FDR) threshold of 0.05. All SNPs coordinates were lifted over to hg38 and their IDs were converted into dbSNP 90 v150 to match SNPs IDs used in GWAS catalog.
Differentially expressed genes. We obtained asthma and hypertension expression signatures from the two biggest expression profiling studies of blood pressure 71 and asthma 91 . From Huan et al. we took 34 genes with expressions associated with hypertension diagnosis or with systolic and diastolic blood pressure. Asthma expression signature included 541 genes differentially expressed in the blood of asthma patients in Bigler et al. dataset. In addition to these two signatures, we composed two lists of genes that demonstrated altered expression levels in asthma or hypertension according to ANDSystem (published on 09.10.2014) and DisGeNET v5.0. These two resources provide collections of differentially expressed genes automatically extracted from biomedical literature. To reduce false positives, we took genes whose altered expression in asthma and hypertension was supported by at least two evidence sources.
Drugs and drug targets. Drugs indicated and contraindicated in asthma and hypertension were obtained from DrugBank 92 v5.0.9 and NDF-RT 93 (released on 02. 10.2017) . Surprisingly, 5 anti-asthmatic drugs (budesonide, flunisolide, salmeterol, formoterol, and cromoglicic acid) were at the same time contraindicated in asthma according to NDF-RT. These drugs are known to cause paradoxical drug reactions, for example, when the intake of an anti-asthmatic drug provokes bronchospasm 94 . We excluded such drugs from contraindications list but kept them in the list of indications, because paradoxical reactions are extremely rare. Finally, the list of contraindicated drugs was extended with drugs reported to induce the rise of blood pressure and asthma, NERD or bronchospasms. From DrugBank, we obtained genes targeted by selected drugs. All target genes encoding non-human proteins were excluded. All drug action types used in DrugBank were converted to simplified effects reflecting the direction of drug action on its target, e.g. "positive" for agonists and activators, "negative" for inhibitors and antagonists, and "other" for modifiers. Supplementary Table S3 contains selected drugs, their effects on diseases and their targets.
Statistical tests. Gene set overrepresentation tests were carried out in TargetMine 95 (build 20180327) with default parameters (one-tailed Fisher's exact test followed by Benjamini-Hochberg correction for multiple testing; Figure 3 . Relationships between genes and drugs indicated and contraindicated in asthma and hypertension. All target genes significantly overrepresented in one of four drug groups are shown. Drugs influencing both diseases and target genes overrepresented in more than one group are shown with bold frames.
Dataset samples Tissue or cell type Cis-eQTLs Trans-eQTLs
GTEx v6 449 44 tissues including whole blood 639825 24
Westra et al. 87 5311 PBMC 397310 349
Joehanes et al. 86 5257 whole blood 2072003 149592
Jansen et al. 88 4896 whole blood 1212555 6913 Table 3 . Characteristics of eQTL datasets.
